Published in N Engl J Med on May 13, 2010
Comparing Voiding Trials After Midurethral Sling for Stress Incontinence | NCT02400034
Bolus Versus Continuous Infusion of Meropenem (MERCY) | NCT03452839
Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase. Clin Infect Dis (2011) 3.06
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.58
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother (2013) 1.50
Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc Natl Acad Sci U S A (2011) 1.48
Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. Am J Infect Control (2016) 1.47
Evaluation of an automated rapid diagnostic assay for detection of Gram-negative bacteria and their drug-resistance genes in positive blood cultures. PLoS One (2014) 1.39
Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J (2011) 1.33
Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J (2011) 1.29
Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother (2013) 1.27
The Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection. J Clin Microbiol (2016) 1.26
The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol (2015) 1.25
Escherichia coli in Europe: an overview. Int J Environ Res Public Health (2013) 1.21
Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles. Antimicrob Agents Chemother (2011) 1.20
A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis (2013) 1.20
Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control (2014) 1.20
Screening for urinary tract infection with the Sysmex UF-1000i urine flow cytometer. J Clin Microbiol (2011) 1.17
Comparison of an in-house method and the commercial Sepsityper™ kit for bacterial identification directly from positive blood culture broths by matrix-assisted laser desorption-ionisation time-of-flight mass spectrometry. Eur J Clin Microbiol Infect Dis (2012) 1.16
Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. EBioMedicine (2015) 1.12
Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University Hospital. BMC Infect Dis (2012) 1.10
Crystal structure of a covalent intermediate in DNA cleavage and rejoining by Escherichia coli DNA topoisomerase I. Proc Natl Acad Sci U S A (2011) 1.06
Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) (2014) 1.05
High prevalence of KPC-2-type carbapenemase coupled with CTX-M-type extended-spectrum beta-lactamases in carbapenem-resistant Klebsiella pneumoniae in a teaching hospital in China. Antimicrob Agents Chemother (2011) 1.04
Pseudomonas aeruginosa biofilms in disease. Microb Ecol (2013) 1.02
Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother (2014) 1.02
The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit. Crit Care (2012) 1.00
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2013) 0.99
The Japanese guidelines for the management of sepsis. J Intensive Care (2014) 0.99
Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. Pharmaceuticals (Basel) (2013) 0.98
Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae. PLoS One (2015) 0.98
Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond. J Bacteriol (2015) 0.97
Antibacterial studies of cationic polymers with alternating, random, and uniform backbones. ACS Chem Biol (2011) 0.97
Strategy for rapid identification and antibiotic susceptibility testing of gram-negative bacteria directly recovered from positive blood cultures using the Bruker MALDI Biotyper and the BD Phoenix system. J Clin Microbiol (2012) 0.97
TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection. PLoS Pathog (2014) 0.97
Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague. J Immunol (2011) 0.96
Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob Agents Chemother (2013) 0.95
Stress responses in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol (2013) 0.93
Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study. Interdiscip Perspect Infect Dis (2012) 0.93
Receptor-interacting protein 2 controls pulmonary host defense to Escherichia coli infection via the regulation of interleukin-17A. Infect Immun (2011) 0.92
Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae. Sci Rep (2015) 0.91
Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Med Sci Monit (2015) 0.91
Clinical Impact of Laboratory Implementation of Verigene BC-GN Microarray-Based Assay for Detection of Gram-Negative Bacteria in Positive Blood Cultures. J Clin Microbiol (2016) 0.91
Isolation and partial characterization of cyclic lipopeptide antibiotics produced by Paenibacillus ehimensis B7. BMC Microbiol (2013) 0.90
The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence (2013) 0.89
Growth-dependent bacterial susceptibility to ribosome-targeting antibiotics. Mol Syst Biol (2015) 0.89
Host susceptibility to gram-negative pneumonia after lung contusion. J Trauma Acute Care Surg (2012) 0.88
Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling (2013) 0.88
Globally dispersed mobile drug-resistance genes in gram-negative bacterial isolates from patients with bloodstream infections in a US urban general hospital. J Med Microbiol (2012) 0.88
Heterogeneity of lung mononuclear phagocytes during pneumonia: contribution of chemokine receptors. Am J Physiol Lung Cell Mol Physiol (2013) 0.87
Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010. BMC Res Notes (2012) 0.87
Exploring bacterial diversity in hospital environments by GS-FLX Titanium pyrosequencing. PLoS One (2012) 0.87
Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit. J Pediatr Pharmacol Ther (2014) 0.87
Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis (2013) 0.86
Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS One (2013) 0.86
Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses. PLoS One (2015) 0.86
Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties. Biochim Biophys Acta (2013) 0.86
Antimicrobial and antiprotozoal activities of secondary metabolites from the fungus Eurotium repens. Med Chem Res (2011) 0.85
Distinct Contributions of Neutrophils and CCR2+ Monocytes to Pulmonary Clearance of Different Klebsiella pneumoniae Strains. Infect Immun (2015) 0.85
Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity. Antimicrob Agents Chemother (2014) 0.85
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2012) 0.85
A Stewardship Approach To Optimize Antimicrobial Therapy through Use of a Rapid Microarray Assay on Blood Cultures Positive for Gram-Negative Bacteria. J Clin Microbiol (2015) 0.84
Multi-disciplinary antimicrobial strategies for improving orthopaedic implants to prevent prosthetic joint infections in hip and knee. J Orthop Res (2015) 0.84
Biofunctionalization of silicone polymers using poly(amidoamine) dendrimers and a mannose derivative for prolonged interference against pathogen colonization. Biomaterials (2011) 0.84
Antibiotic resistance: a primer and call to action. Health Commun (2014) 0.84
Risk factors for the first episode of Klebsiella pneumoniae resistant to carbapenems infection in critically ill patients: a prospective study. Biomed Res Int (2013) 0.83
Genotypic and phenotypic applications for the differentiation and species-level identification of achromobacter for clinical diagnoses. PLoS One (2014) 0.83
Polymyxin use associated with respiratory arrest. Chest (2012) 0.83
Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorg Med Chem (2015) 0.83
Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy. BMC Anesthesiol (2015) 0.83
Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol (2014) 0.83
Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study. Eur J Clin Microbiol Infect Dis (2011) 0.82
Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother (2011) 0.82
Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother (2014) 0.82
Increasing incidence of hospital-acquired and healthcare-associated bacteremia in northeast Thailand: a multicenter surveillance study. PLoS One (2014) 0.82
Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation. Mucosal Immunol (2015) 0.81
A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis. BMC Microbiol (2011) 0.81
Prevalence and Molecular Characterization of Plasmid-mediated Extended-Spectrum β-Lactamase Genes (balaTEM, blaCTX and blASHV) Among Urinary Escherichia coli Clinical Isolates in Mashhad, Iran. Iran J Basic Med Sci (2012) 0.81
Comparative evaluation of Vitek 2 identification and susceptibility testing of urinary tract pathogens directly and isolated from chromogenic media. Eur J Clin Microbiol Infect Dis (2013) 0.81
Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection. PLoS One (2017) 0.80
Predicting frequent hospital admission risk in Singapore: a retrospective cohort study to investigate the impact of comorbidities, acute illness burden and social determinants of health. BMJ Open (2016) 0.80
A broad-spectrum antimicrobial activity of Bacillus subtilis RLID 12.1. ScientificWorldJournal (2014) 0.80
Colonization with resistant microorganisms in patients transferred from abroad: who needs to be screened? Antimicrob Resist Infect Control (2015) 0.80
The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes. Eur Spine J (2013) 0.80
Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. J Am Chem Soc (2012) 0.80
Sloth hair as a novel source of fungi with potent anti-parasitic, anti-cancer and anti-bacterial bioactivity. PLoS One (2014) 0.80
Induction of STAT3-Dependent CXCL5 Expression and Neutrophil Recruitment by Oncostatin-M during Pneumonia. Am J Respir Cell Mol Biol (2015) 0.80
Shiga (Vero)-toxin producing Escherichia coli isolated from the hospital foods; virulence factors, o-serogroups and antimicrobial resistance properties. Antimicrob Resist Infect Control (2017) 0.79
Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Innate Immun (2013) 0.79
Exploring Dangerous Connections between Klebsiella pneumoniae Biofilms and Healthcare-Associated Infections. Pathogens (2014) 0.79
Thioflavin T as a fluorescence probe for monitoring RNA metabolism at molecular and cellular levels. Nucleic Acids Res (2015) 0.79
Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis (2015) 0.79
A real-time PCR-based semi-quantitative breakpoint to aid in molecular identification of urinary tract infections. PLoS One (2013) 0.79
Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates. PLoS One (2013) 0.79
From microbial gene essentiality to novel antimicrobial drug targets. BMC Genomics (2014) 0.79
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 0.79
Quorum Sensing Inhibiting Activity of Streptomyces coelicoflavus Isolated from Soil. Front Microbiol (2016) 0.79
Evaluation of BiesseBioscreen as a new methodology for bacteriuria screening. New Microbiol (2014) 0.79
Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital. J Res Pharm Pract (2015) 0.78
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med (2006) 24.54
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis (2009) 15.19
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol (2008) 13.49
Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep (2007) 11.94
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 11.12
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 9.51
Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis (2005) 9.06
Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med (2002) 8.67
Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother (2007) 7.81
Deaths: final data for 2005. Natl Vital Stat Rep (2008) 7.50
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest (2005) 5.91
Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med (2004) 5.74
A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med (2006) 5.74
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 4.84
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest (2002) 3.98
Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med (2000) 3.89
Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep (2004) 3.84
Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med (2007) 2.94
First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother (2008) 2.93
Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med (2007) 2.69
Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev (2008) 2.45
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med (2000) 2.19
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill (2008) 2.13
Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol (2009) 2.02
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother (2006) 1.99
Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis (2008) 1.96
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med (2008) 1.94
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.81
Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care (2008) 1.76
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother (2008) 1.75
Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med (2008) 1.58
Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology (2002) 1.49
European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents (2007) 1.48
Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother (2008) 1.46
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother (2005) 1.41
The Lowbury Lecture. The United States approach to strategies in the battle against healthcare-associated infections, 2006: transitioning from benchmarking to zero tolerance and clinician accountability. J Hosp Infect (2007) 1.12
The economic impact of infection control: making the business case for increased infection control resources. Am J Infect Control (2005) 1.08
Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med (2007) 1.05
Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis (2008) 1.03
Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev (2008) 1.02
Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. J Crit Care (2008) 0.90
The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. J Crit Care (2008) 0.89
The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis (2006) 7.20
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2005) 7.15
Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother (2003) 6.26
qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother (2006) 5.50
Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother (2006) 4.96
Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev (2009) 4.43
Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother (2005) 4.03
Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med (2008) 3.88
Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis (2013) 3.78
Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis (2006) 3.66
Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis (2013) 3.56
Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother (2004) 3.54
Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother (2005) 2.90
Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother (2008) 2.70
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother (2009) 2.32
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Case records of the Massachusetts General Hospital. Case 3-2015. A 60-year-old woman with abdominal pain, dyspnea, and diplopia. N Engl J Med (2015) 1.97
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother (2009) 1.77
Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis (2013) 1.57
Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis (2004) 1.56
NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol (2008) 1.47
Recurrent meningitis of unknown aetiology. Lancet (2004) 1.43
A recA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus. J Biol Chem (2003) 1.41
NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.37
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother (2002) 1.34
Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.30
Mechanistic and structural analysis of aminoglycoside N-acetyltransferase AAC(6')-Ib and its bifunctional, fluoroquinolone-active AAC(6')-Ib-cr variant. Biochemistry (2008) 1.27
Detection of postoperative surgical-site infections: comparison of health plan-based surveillance with hospital-based programs. Infect Control Hosp Epidemiol (2003) 1.27
Citrobacter spp. as a source of qnrB Alleles. Antimicrob Agents Chemother (2011) 1.26
The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus. J Bacteriol (2007) 1.26
Transferable quinolone resistance in Vibrio cholerae. Antimicrob Agents Chemother (2009) 1.22
Temporal appearance of plasmid-mediated quinolone resistance genes. Antimicrob Agents Chemother (2009) 1.17
SOS regulation of qnrB expression. Antimicrob Agents Chemother (2008) 1.16
Enhanced surgical site infection surveillance following hysterectomy, vascular, and colorectal surgery. Infect Control Hosp Epidemiol (2012) 1.14
Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. J Biol Chem (2011) 1.13
Quinolone resistance due to reduced target enzyme expression. J Bacteriol (2003) 1.13
CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 28-2015. A 32-Year-Old Man with Fever, Headache, and Myalgias after Traveling from Liberia. N Engl J Med (2015) 1.13
Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997-2007. Clin Infect Dis (2012) 1.12
Epidemiology of dermatitis and skin infections in United States physicians' offices, 1993-2005. Clin Infect Dis (2009) 1.10
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol (2002) 1.10
Use of Medicare diagnosis and procedure codes to improve detection of surgical site infections following hip arthroplasty, knee arthroplasty, and vascular surgery. Infect Control Hosp Epidemiol (2011) 1.09
Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother (2004) 1.08
Posttranslational modification influences the effects of MgrA on norA expression in Staphylococcus aureus. J Bacteriol (2008) 1.07
Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect Dis (2014) 1.04
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 1.03
Antibiotic dosing before primary hip and knee replacement as a pay-for-performance measure. J Bone Joint Surg Am (2007) 1.02
Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus. J Bacteriol (2010) 1.02
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.98
Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother (2011) 0.97
Resource burden associated with contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: the patient access managers' perspective. Infect Control Hosp Epidemiol (2012) 0.94
Staphylococcus aureus NorD, a putative efflux pump coregulated with the Opp1 oligopeptide permease, contributes selectively to fitness in vivo. J Bacteriol (2012) 0.94
Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis (2014) 0.92
DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother (2005) 0.91
Phylogenetic analysis of chromosomally determined qnr and related proteins. Antimicrob Agents Chemother (2013) 0.90
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob Agents Chemother (2002) 0.90
Native efflux pumps contribute resistance to antimicrobials of skin and the ability of Staphylococcus aureus to colonize skin. J Infect Dis (2013) 0.89
Mutational analysis of quinolone resistance protein QnrB1. Antimicrob Agents Chemother (2013) 0.89
National survey of infection preventionists: policies for discontinuation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. Infect Control Hosp Epidemiol (2012) 0.88
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother (2006) 0.88
An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr Purif (2005) 0.88
Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea. J Antimicrob Chemother (2013) 0.87
Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA. J Bacteriol (2012) 0.87
Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin. Antimicrob Agents Chemother (2011) 0.85
Quinolone induction of qnrVS1 in Vibrio splendidus and plasmid-carried qnrS1 in Escherichia coli, a mechanism independent of the SOS system. Antimicrob Agents Chemother (2011) 0.83
Cold shock induces qnrA expression in Shewanella algae. Antimicrob Agents Chemother (2010) 0.82
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem (2005) 0.82
Induction of plasmid-carried qnrS1 in Escherichia coli by naturally occurring quinolones and quorum-sensing signal molecules. Antimicrob Agents Chemother (2013) 0.80
Regulation of expression of abcA and its response to environmental conditions. J Bacteriol (2014) 0.79
Fungus-infected fluid collections in thorax or abdomen: effectiveness of percutaneous catheter drainage. Radiology (2005) 0.79
Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother (2013) 0.79
Concordance of PCR and culture from nasal swabs for detection of methicillin-resistant Staphylococcus aureus in a setting of concurrent antistaphylococcal antibiotics. J Clin Microbiol (2014) 0.76
Severe babesiosis in a patient treated with a tumor necrosis factor α antagonist. Clin Infect Dis (2012) 0.75